TRCT
EDIT icon

Tower Research Capital (TRC)’s Editas Medicine EDIT Stock Holding History

Tower Research Capital (TRC)’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7K Sell
7,162
-7,224
-50% -$15.3K ﹤0.01% 3568
2025
Q4 		$29.5K Buy
14,386
+10,668
+287% +$30.8K ﹤0.01% 2819
2025
Q3 		$12.9K Sell
3,718
-12,207
-77% -$34.1K ﹤0.01% 3738
2025
Q2 		$35K Buy
15,925
+901
+6% +$1.47K ﹤0.01% 3280
2025
Q1 		$17.5K Sell
15,024
-4,437
-23% -$6.53K ﹤0.01% 3104
2024
Q4 		$24.7K Sell
19,461
-26,628
-58% -$67.8K ﹤0.01% 3034
2024
Q3 		$157K Buy
46,089
+25,201
+121% +$110K ﹤0.01% 1852
2024
Q2 		$97.5K Buy
20,888
+20,077
+2,476% +$113K ﹤0.01% 2604
2024
Q1 		$6.02K Sell
811
-5,621
-87% -$46.7K ﹤0.01% 4449
2023
Q4 		$65.2K Sell
6,432
-14,477
-69% -$127K ﹤0.01% 2954
2023
Q3 		$163K Buy
20,909
+4,713
+29% +$40.4K 0.01% 1575
2023
Q2 		$133K Buy
16,196
+11,509
+246% +$100K ﹤0.01% 1848
2023
Q1 		$34K Sell
4,687
-22,786
-83% -$203K ﹤0.01% 2861
2022
Q4 		$243K Buy
27,473
+2,916
+12% +$32K 0.01% 1180
2022
Q3 		$300K Sell
24,557
-20,504
-46% -$319K ﹤0.01% 1554
2022
Q2 		$533K Buy
45,061
+40,453
+878% +$542K 0.01% 1100
2022
Q1 		$87K Sell
4,608
-4,382
-49% -$81.5K ﹤0.01% 2312
2021
Q4 		$238K Buy
8,990
+2,786
+45% +$95.9K ﹤0.01% 1628
2021
Q3 		$254K Buy
6,204
+3,253
+110% +$178K 0.01% 1584
2021
Q2 		$167K Sell
2,951
-48,487
-94% -$1.79M ﹤0.01% 2051
2021
Q1 		$2.16M Buy
51,438
+49,570
+2,654% +$2.82M 0.04% 457
2020
Q4 		$131K Sell
1,868
-7,690
-80% -$316K ﹤0.01% 2097
2020
Q3 		$269K Sell
9,558
-1,561
-14% -$50.8K ﹤0.01% 2278
2020
Q2 		$329K Buy
+11,119
New +$291K 0.01% 1365
2019
Q4 		– Sell
-1,093
Closed -$25K – 3728
2019
Q3 		$25K Buy
+1,093
New +$27.1K ﹤0.01% 2310
2019
Q2 		– Sell
-284
Closed -$7K – 3829
2019
Q1 		$7K Sell
284
-561
-66% -$12.7K ﹤0.01% 2860
2018
Q4 		$19K Sell
845
-6,086
-88% -$166K ﹤0.01% 1976
2018
Q3 		$221K Buy
6,931
+6,834
+7,045% +$221K 0.02% 925
2018
Q2 		$3K Sell
97
-5
-5% -$177 ﹤0.01% 3215
2018
Q1 		$3K Sell
102
-77
-43% -$2.74K ﹤0.01% 2853
2017
Q4 		$6K Sell
179
-1,544
-90% -$38.9K ﹤0.01% 2807
2017
Q3 		$41K Sell
1,723
-262
-13% -$4.99K ﹤0.01% 2146
2017
Q2 		$33K Buy
+1,985
New +$35.8K ﹤0.01% 957
2017
Q1 		– Sell
-745
Closed -$12K – 3231
2016
Q4 		$12K Buy
+745
New +$11.3K ﹤0.01% 2519
2016
Q3 		– Sell
-647
Closed -$16K – 3800
2016
Q2 		$16K Buy
+647
New +$21.8K ﹤0.01% 2411

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tower Research Capital (TRC)'s EDIT Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Editas Medicine (EDIT) stake by 50% in Q1 2026, selling an estimated $15.3K and leaving 7,162 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3568.

Tower Research Capital (TRC) first reported a position in EDIT in Q2 2016 and has held it in 35 quarters since. The position peaked at $2.16M in Q1 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Tower Research Capital (TRC) held 7,162 shares of Editas Medicine worth $17.7K as of Q1 2026.
  • Tower Research Capital (TRC) sold 7,224 Editas Medicine shares in Q1 2026, an estimated $15.3K.
  • Editas Medicine made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3568 holding.
  • Tower Research Capital (TRC) first reported a position in Editas Medicine in Q2 2016 and has held it in 35 quarters since.
  • Tower Research Capital (TRC)'s Editas Medicine position peaked at $2.16M in Q1 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.